Protagonist Therapeutics Inc (NASDAQ:PTGX)’s share price shot up 7.8% on Monday . The company traded as high as $11.12 and last traded at $11.04, 124,734 shares traded hands during trading. A decline of 36% from the average session volume of 193,691 shares. The stock had previously closed at $10.24.

A number of research firms have recently weighed in on PTGX. ValuEngine raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. Nomura reaffirmed a “buy” rating and set a $29.00 price objective on shares of Protagonist Therapeutics in a research report on Sunday, August 11th. BidaskClub raised Protagonist Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Zacks Investment Research lowered Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th. Finally, Svb Leerink reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research report on Tuesday, August 13th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $19.60.

The stock has a market cap of $311.42 million, a PE ratio of -6.81 and a beta of 1.87. The firm has a fifty day moving average of $11.60 and a 200 day moving average of $10.78. The company has a quick ratio of 4.12, a current ratio of 4.12 and a debt-to-equity ratio of 0.08.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Wednesday, August 7th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.90). The business had revenue of ($8.19) million during the quarter, compared to analysts’ expectations of $10.77 million. Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 62.50%. On average, equities research analysts forecast that Protagonist Therapeutics Inc will post -2.65 EPS for the current fiscal year.

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 10,792 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $8.85, for a total value of $95,509.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Y. Liu sold 3,395 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $8.85, for a total transaction of $30,045.75. The disclosure for this sale can be found here. Corporate insiders own 14.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PTGX. BlackRock Inc. increased its holdings in shares of Protagonist Therapeutics by 8.8% in the 4th quarter. BlackRock Inc. now owns 260,548 shares of the company’s stock valued at $1,754,000 after acquiring an additional 21,126 shares during the period. Northern Trust Corp increased its holdings in shares of Protagonist Therapeutics by 17.2% in the 4th quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock valued at $234,000 after acquiring an additional 5,084 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Protagonist Therapeutics by 33.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 490,267 shares of the company’s stock valued at $3,299,000 after acquiring an additional 122,250 shares during the period. Bank of America Corp DE increased its holdings in shares of Protagonist Therapeutics by 94.3% in the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock valued at $178,000 after acquiring an additional 12,819 shares during the period. Finally, Bank of Montreal Can increased its holdings in shares of Protagonist Therapeutics by 1,675.5% in the 1st quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock valued at $139,000 after acquiring an additional 10,405 shares during the period. Institutional investors own 61.65% of the company’s stock.

About Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Further Reading: How to Track your Portfolio in Google Finance

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.